SKBI [SKYSTAR BIO-PHARMACEUTICAL] 8-K: December 17, 2010 405 Fifth Street, NW Gentlemen:

[December 17, 2010 405 Fifth Street, NW Gentlemen: 135 South Statellege Boulevard, Suite 300 | Brea,lifornia 92821 | 714.990.1040 | frazerfrost.com Los Angeles and Visalia, | Little Rock and Fayetteville, AR | Raleigh, NC F R AZER FROST, v205591_ex16-1.htm 2 EX-16.1] [NEWS RELEASEystar Bio-Pharmaceutical Appoints Crowe Horwath New Independent Auditor XIAN, CHINA December 15, 2010 -- -ystar Bio-Pharmaceuticalmpany (NASDAQ:SKBI) ("Skystar" or the "Company"), To beded to thempany's email distribution for future news releases, please send your request toystar@grayling.com.out Crowe Horwathoutystar Bio-Pharmaceuticalmpany]

By | 2016-02-05T03:49:51+00:00 December 17th, 2010|Categories: Chinese Stocks, SKBI, Webplus ver|Tags: , , , , , |0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] DEF 14A: Payment of Filing Fee (Check the appropriate box):

[Payment of Filing Fee (Check the appropriate box): x No fee required. o Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11. 1) Title of each class of securities to which transaction applies:]

By | 2016-03-01T05:37:42+00:00 December 3rd, 2010|Categories: Chinese Stocks, SKBI, Webplus ver|Tags: , , , , , |0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL] DEF 14A: (Original Filing)

[Payment of Filing Fee (Check the appropriate box): x No fee required. o Feemputed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11. 1) Title of each class of securities to which transaction applies: 2)gregate number of securities to which transaction applies: 3) 4) Proposed maximumgregate value of transaction:]

By | 2016-02-05T03:50:34+00:00 December 3rd, 2010|Categories: Chinese Stocks, SEC Original, SKBI|Tags: , , , , , |0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL] DEF 14A: Payment of Filing Fee (Check the appropriate box):

[Payment of Filing Fee (Check the appropriate box): x No fee required. o Feemputed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11. 1) Title of each class of securities to which transaction applies: 2)gregate number of securities to which transaction applies: 3) 4) Proposed maximumgregate value of transaction:]

By | 2016-02-05T03:51:29+00:00 December 3rd, 2010|Categories: Chinese Stocks, SKBI, Webplus ver|Tags: , , , , , |0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 8-K: (Original Filing)

[NEWS RELEASE Skystar Bio-Pharmaceutical Announces Record Organic Revenues of $18.5 Million For Third Quarter Fiscal Year 2010 - Company reiterates fiscal 2010 guidance of $45.5 Million to $47.5 Million - XI’AN, CHINA – November 16, 2010 -- - Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) ("Skystar" or the "Company"), Third Quarter 2010 Highlights · Revenue increases 45% YoY to record $18.5 million ·]

By | 2016-03-01T05:39:27+00:00 November 16th, 2010|Categories: Chinese Stocks, SEC Original, SKBI|Tags: , , , , , |0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 8-K: NEWS RELEASE Skystar Bio-Pharmaceutical Announces Record Organic Revenues

[NEWS RELEASE Skystar Bio-Pharmaceutical Announces Record Organic Revenues of $18.5 Million For Third Quarter Fiscal Year 2010 - Company reiterates fiscal 2010 guidance of $45.5 Million to $47.5 Million - XI’AN, CHINA – November 16, 2010 -- - Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) ("Skystar" or the "Company"), Third Quarter 2010 Highlights · Revenue increases 45% YoY to record $18.5 million ·]

By | 2016-03-01T05:40:10+00:00 November 16th, 2010|Categories: Chinese Stocks, SKBI, Webplus ver|Tags: , , , , , |0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL] 8-K: (Original Filing)

[NEWS RELEASEystar Bio-Pharmaceutical Announces Record Organic Revenues of $18.5 Million For Third Quarter Fiscal Year 2010 -mpany reiterates fiscal 2010 guidance of $45.5 Million to $47.5 Million - XIAN, CHINA November 16, 2010 -- -ystar Bio-Pharmaceuticalmpany (NASDAQ:SKBI) ("Skystar" or the "Company"), Third Quarter 2010 Highlights Revenuereases 45% YoY to record $18.5 million]

By | 2016-02-05T03:52:45+00:00 November 16th, 2010|Categories: Chinese Stocks, SEC Original, SKBI|Tags: , , , , , |0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL] 8-K: NEWS RELEASEystar Bio-Pharmaceutical Announces Record Organic Revenues of

[NEWS RELEASEystar Bio-Pharmaceutical Announces Record Organic Revenues of $18.5 Million For Third Quarter Fiscal Year 2010 -mpany reiterates fiscal 2010 guidance of $45.5 Million to $47.5 Million - XIAN, CHINA November 16, 2010 -- -ystar Bio-Pharmaceuticalmpany (NASDAQ:SKBI) ("Skystar" or the "Company"), Third Quarter 2010 Highlights Revenuereases 45% YoY to record $18.5 million]

By | 2016-02-05T03:53:35+00:00 November 16th, 2010|Categories: Chinese Stocks, SKBI, Webplus ver|Tags: , , , , , |0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 10-Q: SKYSTAR BIO-PHARMACEUTICAL COMPANY FORM 10-Q INDEX Page Number

[SKYSTAR BIO-PHARMACEUTICAL COMPANY FORM 10-Q INDEX Page Number PART I. FINANCIAL INFORMATION Item 1.] [CERTIFICATE OF AMENDMENT AND CERTIFICATE OF CHANGE EX-3.1 3 v202562_ex3-1.htm] [CERTIFICATION I, Weibing Lu, certify that: 1. I have reviewed this Quarterly 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period] [CERTIFICATION I, Michael H. Lan, certify that: 1. I have reviewed this Quarterly 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the] [CERTIFICATION (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Weibing Lu Chief Executive Officer EX-32.1 37 v202562_ex32-1.htm] [CERTIFICATION (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Michael H. Lan Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 38 v202562_ex32-2.htm]

By | 2016-03-01T05:43:36+00:00 November 15th, 2010|Categories: Chinese Stocks, SKBI, Webplus ver|Tags: , , , , , |0 Comments
Skip to toolbar